Lyell Immunopharma Reports $274.4 Million Net Loss for 2025, Decreases in R&D Expenses

Lyell Immunopharma, Inc. reported a net loss of $274.4 million for the year ended December 31, 2025, compared to a net loss of $343.0 million for the previous year. The company, a late-stage clinical cell therapy firm, has yet to generate revenue from product sales, reporting only $36,000 in revenue for 2025, a decrease from $61,000 in 2024. Research and development expenses totaled $158.7 million, a decrease from $171.6 million in the prior year, while general and administrative expenses also decreased to $45.1 million from $52.0 million. These decreases were partially offset by acquired in-process research and development expenses of $66.3 million and impairment of long-lived assets of $1.4 million.

The company's financial performance reflects significant investments in its pipeline programs, particularly ronde-cel and LYL273. Research and development expenses included personnel costs, research activities, and facility-related costs. The decrease in research and development expenses was primarily due to a reduction in personnel-related expenses and facilities, technology and depreciation expenses, partially offset by an increase in research activities, collaborations, outside services and other expenses. The company's cash, cash equivalents, and marketable securities totaled $247.2 million as of December 31, 2025.

Strategic developments for Lyell Immunopharma in 2025 included the acquisition of an exclusive global license for LYL273, a novel GCC-targeted CAR T-cell product candidate, from Innovative Cellular Therapeutics (ICT) for an upfront payment of $40 million in cash and the issuance of 1.9 million shares of common stock. ICT is also eligible for potential milestone payments and royalties on future net sales. The company also continued to advance its lead product candidate, ronde-cel, through ongoing clinical trials, including the initiation of a Phase 3 randomized controlled head-to-head trial.

Key operational developments included the continued advancement of ronde-cel through pivotal clinical trials and the ongoing Phase 1 clinical program evaluating LYL273. The company also presented updated clinical data from its ronde-cel program at the American Society of Hematology (ASH) Annual Meeting and Exposition in December 2025. As of December 31, 2025, the company had 161 employees, with over 80% engaged in research and development activities, technical operations, and process sciences.

Looking ahead, Lyell Immunopharma anticipates that its research and development expenses will increase as it continues to advance its pipeline programs and seek regulatory approvals. The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to meet its working capital and capital expenditure needs into the second quarter of 2027. However, the company expects to require additional capital to complete clinical development and commercialization of its product candidates. The company's future success is dependent on the successful development and regulatory approval of its product candidates, as well as its ability to manufacture and commercialize these products effectively.